Mizuno Tomohito, Endo Yoko, Suzuki Atsushi, Suzuki Masashi
Department of Internal Medicine, Division of Nephrology, Tokyo Yamate Medical Center, Tokyo, JPN.
Department of Pathology, Tokyo Yamate Medical Center, Tokyo, JPN.
Cureus. 2024 Mar 12;16(3):e56028. doi: 10.7759/cureus.56028. eCollection 2024 Mar.
Although immunoglobulin G4 (IgG4)-related kidney diseases are typically characterized by tubulointerstitial nephritis with abundant infiltration of IgG4-positive plasma cells and fibrosis, there have been relatively rare cases of IgG4-related glomerulonephritis. Several cases of IgG4-related disease (IgG4-RD) following coronavirus disease 2019 (COVID-19) mRNA vaccination have been reported. However, there are no reports of IgG4-related glomerulonephritis following COVID-19 vaccination. Herein, we present a case of IgG4-related membranous nephropathy (MN) occurring after COVID-19 vaccination. A 69-year-old Japanese male presented to our hospital with edema that started the day after his second COVID-19 vaccination. The patient exhibited nephrotic syndrome and was diagnosed with MN based on the results of a kidney biopsy. Although serum IgG4 levels were elevated to 946 mg/dL, no evidence of organ involvement suggestive of IgG4-RD was observed. Treatment with prednisolone and cyclosporine resulted in complete remission, and immunosuppressive agents were tapered. However, one month after discontinuing the immunosuppressive agents, the patient was readmitted with swelling around the submandibular glands and exertional dyspnea. Serum IgG4 level was markedly elevated at 2,320 mg/dL, and computed tomography revealed submandibular gland swelling and thickening of the interlobular septum and bronchovascular bundles in both lungs. The patient was diagnosed with IgG4-RD based on elevated serum IgG4 levels and infiltration of IgG4-positive plasma cells in the submandibular gland biopsy. Upon resuming treatment with prednisolone, the symptoms attributed to IgG4-RD improved within a few days. In cases of nephrotic syndrome following COVID-19 vaccination, it may be advisable to conduct detailed examinations to assess the possibility of the development of IgG4-RDs.
尽管免疫球蛋白G4(IgG4)相关肾病通常以肾小管间质性肾炎为特征,伴有IgG4阳性浆细胞大量浸润和纤维化,但IgG4相关肾小球肾炎的病例相对罕见。已有数例2019冠状病毒病(COVID-19)mRNA疫苗接种后发生IgG4相关疾病(IgG4-RD)的报道。然而,尚无COVID-19疫苗接种后发生IgG4相关肾小球肾炎的报道。在此,我们报告1例COVID-19疫苗接种后发生的IgG4相关膜性肾病(MN)。一名69岁的日本男性在第二次接种COVID-19疫苗后次日出现水肿,前来我院就诊。患者表现为肾病综合征,根据肾活检结果诊断为MN。尽管血清IgG4水平升高至946mg/dL,但未观察到提示IgG4-RD的器官受累证据。泼尼松龙和环孢素治疗后完全缓解,免疫抑制剂逐渐减量。然而,停用免疫抑制剂1个月后,患者因颌下腺周围肿胀和劳力性呼吸困难再次入院。血清IgG4水平显著升高至2320mg/dL,计算机断层扫描显示颌下腺肿大,双肺小叶间隔和支气管血管束增厚。根据血清IgG4水平升高及颌下腺活检中IgG4阳性浆细胞浸润,患者被诊断为IgG4-RD。重新使用泼尼松龙治疗后,IgG4-RD相关症状在数天内得到改善。对于COVID-19疫苗接种后出现肾病综合征的病例,可能建议进行详细检查,以评估IgG4-RDs发生的可能性。